VANTAS

This brand name is authorized in United States, South Africa

Active ingredients

The drug VANTAS contains one active pharmaceutical ingredient (API):

1 Histrelin UNII QMG7HLD1ZE - HISTRELIN ACETATE

Histrelin is a gonadotropin releasing hormone (GnRH) agonist and an inhibitor of gonadotropin secretion when given continuously. It is indicated for the treatment of children with central precocious puberty (CPP). However, continuous administration of histrelin acetate causes a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. Read about Histrelin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VANTAS Implant	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02AE05		L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 67979-500
Country: ZA	Health Products Regulatory Authority	Identifier(s): A40/21.10/0621